Podcasts

Escaping the Void: All Things Biosimilars With Craig & G

May 4th 2025

Podcast

To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."

How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment

March 9th 2025

Podcast

Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?

Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals

February 9th 2025

Podcast

In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.

The Top 5 Most-Listened to Podcasts of 2024

December 29th 2024

Article

On this episode of Not So Different, we reflect on 2024 and this show in particular, taking audiences back through the most popular podcast episodes of the year.

Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition

December 1st 2024

Podcast

On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.

Can Global Policies to Boost Biosimilar Adoption Work in the US?

November 17th 2024

Article

On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.

Biosimilars Development Roundup for October 2024—Podcast Edition

November 3rd 2024

Podcast

On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.

Biosimilars Policy Roundup for September 2024—Podcast Edition

October 6th 2024

Podcast

On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.

Biosimilars Business Roundup for August 2024—Podcast Edition

September 1st 2024

Article

On this episode of Not So Different, the end of the second quarter brings with it expense reports, new biosimilar business deals, and insights into how federal policy impacts biosimilar company pursuits.

Biosimilars Policy Roundup for July 2024—Podcast Edition

August 4th 2024

Podcast

On this episode of Not So Different, we review all the big biosimilar policy news from July, including discussions regarding biosimilar policies, in both the US and abroad, as well as 3 highly anticipated FDA approvals.